Filing Flows › Abbott Laboratories (ABT) › Who owns the stock
Who owns Abbott Laboratories (ABT) stock
2,939 funds reported Abbott Laboratories (ABT) shares in their latest 13F filings, worth $143.7B in all. The largest holder is Vanguard Group ($22.0B). Last quarter 1,123 funds added to their stakes and 1516 cut them. Members of Congress and other officials disclosed 26 trades (7 buys, 18 sales).
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Vanguard Group | 175,556,716 | $22.0B | increase | 2025-12-31 |
| BlackRock | 152,563,476 | $13.8B | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 113,750,994 | $10.3B | increase | 2026-06-30 |
| State Street | 80,926,234 | $7.3B | increase | 2026-06-30 |
| Charles Schwab Investment Management | 59,674,507 | $5.4B | increase | 2026-06-30 |
| Vanguard Portfolio Management LLC | 49,017,866 | $4.4B | increase | 2026-06-30 |
| Geode Capital Management, LLC | 39,219,337 | $3.5B | increase | 2026-06-30 |
| Capital Research Global Investors | 36,908,990 | $3.3B | decrease | 2026-06-30 |
| Capital International Investors | 34,654,113 | $3.1B | decrease | 2026-06-30 |
| Morgan Stanley | 26,611,315 | $2.4B | decrease | 2026-06-30 |
| Price T Rowe Associates | 22,787,202 | $2.1B | increase | 2026-06-30 |
| Deutsche Bank Ag\ | 17,693,960 | $1.7B | increase | 2026-09-30 |
| Franklin Resources | 18,806,911 | $1.7B | decrease | 2026-06-30 |
| Northern Trust | 18,273,301 | $1.7B | decrease | 2026-06-30 |
| Bank of America | 17,672,543 | $1.6B | decrease | 2026-06-30 |
Trades by Congress and other officials
| Date | Who | Trade | Amount |
|---|---|---|---|
| 2026-10-02 | Pete Sessions | sale | $50K–$100K |
| 2026-09-18 | Gilbert Cisneros | purchase | $1K–$15K |
| 2026-09-17 | Thomas H. Kean Jr | partial sale | $1K–$15K |
| 2026-07-30 | Richard Dean Dr McCormick | sale | $1K–$15K |
| 2026-07-17 | Mike Kelly | sale | $1K–$15K |
| 2026-07-14 | Richard W. Allen | sale | $15K–$50K |
| 2026-07-08 | Rick Larsen | sale | $1K–$15K |
| 2026-06-16 | Gilbert Cisneros | purchase | $1K–$15K |
| 2026-06-12 | Richard Dean Dr McCormick | purchase | $1K–$15K |
| 2026-05-27 | Josh Gottheimer | partial sale | $1K–$15K |
Abbott Laboratories' latest quarter
Abbott Laboratories, Q3 2026: revenue $13.0B (+14% year over year), operating margin 10.4%, net earnings $920M, operating cash flow $1.7B. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most ABT stock?
By the latest 13F filings: Vanguard Group ($22.0B); BlackRock ($13.8B); Vanguard Capital Management LLC ($10.3B); State Street ($7.3B); Charles Schwab Investment Management ($5.4B).
Has Congress traded ABT stock?
Officials disclosed 26 trades on file: 7 buys and 18 sales. The latest: Pete Sessions, sale on 2026-10-02.
What is the short interest in ABT?
17,386,736 shares were sold short at the 2026-10-15 settlement, 27.52% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.